Special cells, special considerations: the challenges of bringing embryonic stem cells from the laboratory to the clinic
- PMID: 18285783
- PMCID: PMC3044319
- DOI: 10.1038/sj.clpt.6100384
Special cells, special considerations: the challenges of bringing embryonic stem cells from the laboratory to the clinic
Abstract
Human embryonic stem (ES) cells are an attractive tool for cell-based therapies because of their limitless capacity for proliferation and their ability to differentiate into all cell types of the body. However, these features introduce certain unique risks that must be considered in developing transplantation strategies for clinical use. We outline these risks and examine current approaches to address them, both before and after transplantation.
Conflict of interest statement
The authors declared no conflict of interest.
Figures
References
-
- Lu P, Jones LL, Snyder EY, Tuszynski MH. Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Exp Neurol. 2003;181:115–129. - PubMed
-
- Thomson JA, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145–1147. - PubMed
-
- Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA. Functional engraftment of human ES cell–derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med. 2006;12:1259–1268. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
